Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation : Meta-Analysis

DOI DOI Web Site Web Site Web Site ほか2件をすべて表示 一部だけ表示 被引用文献13件 参考文献27件 オープンアクセス
  • Gómez-Molina Miriam
    Department of Cardiology, University Hospital Virgen de la Arrixaca Bio-Health Research Institute Virgen de la Arrixaca. IMIB-Arrixaca
  • Valdés Mariano
    Department of Cardiology, University Hospital Virgen de la Arrixaca Bio-Health Research Institute Virgen de la Arrixaca. IMIB-Arrixaca
  • Marín Francisco
    Department of Cardiology, University Hospital Virgen de la Arrixaca Bio-Health Research Institute Virgen de la Arrixaca. IMIB-Arrixaca

書誌事項

タイトル別名
  • Oral Anticoagulation in Japanese Patients With Atrial Fibrillation
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in Japanese Patients With Atrial Fibrillation
  • Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation—meta-analysis
  • – Insight to the Use of Non-Vitamin K Antagonist Oral Anticoagulants –

この論文をさがす

説明

Background:Non-vitamin K antagonist oral anticoagulants (NOAC) have been developed as alternatives to warfarin. Until recently, the latter was the standard oral anticoagulant for patients with non-valvular atrial fibrillation (NVAF). The efficacy and safety of NOAC in Japanese patients with NVAF has been investigated in small trials or subgroups from global randomized control trials (RCT).Methods and Results:We conducted a systematic review and meta-analysis of RCT, to compare the efficacy and safety of NOAC to those of warfarin in Japanese patients with NVAF. Published research was systematically searched for RCT that compared NOAC to warfarin in Japanese patients with NVAF. Random-effects models were used to pool efficacy and safety data across RCT. Three studies, involving 1,940 patients, were identified. Patients randomized to NOAC had a decreased risk for stroke and systemic thromboembolism (relative risk [RR], 0.45; 95% CI: 0.24–0.85), with a non-significant trend for lower major bleeding (RR, 0.66; 95% CI: 0.29–1.47), intracranial bleeding (RR, 0.46; 95% CI: 0.18–1.16) and gastrointestinal bleeding (RR, 0.52; 95% CI: 0.25–1.08).Conclusions:NOAC are more efficacious than warfarin for the prevention of stroke and systemic embolism in Japanese patients with NVAF. The present findings offer clinicians a more comprehensive picture of NOAC as a therapeutic option to reduce the risk of stroke in Japanese NVAF patients. (Circ J 2015; 79: 339–345)

収録刊行物

  • Circulation Journal

    Circulation Journal 79 (2), 292-294, 2015

    一般社団法人 日本循環器学会

被引用文献 (13)*注記

もっと見る

参考文献 (27)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ